319 related articles for article (PubMed ID: 22834813)
1. Innovative lead compounds and formulation strategies as newer kinetoplastid therapies.
Espuelas S; Plano D; Nguewa P; Font M; Palop JA; Irache JM; Sanmartín C
Curr Med Chem; 2012; 19(25):4259-88. PubMed ID: 22834813
[TBL] [Abstract][Full Text] [Related]
2. The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives.
Castillo E; Dea-Ayuela MA; Bolás-Fernández F; Rangel M; González-Rosende ME
Curr Med Chem; 2010; 17(33):4027-51. PubMed ID: 20939823
[TBL] [Abstract][Full Text] [Related]
3. An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases.
Kourbeli V; Chontzopoulou E; Moschovou K; Pavlos D; Mavromoustakos T; Papanastasiou IP
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361781
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
[TBL] [Abstract][Full Text] [Related]
5. Novel compounds to combat trypanosomatid infections: a medicinal chemical perspective.
González M; Cerecetto H
Expert Opin Ther Pat; 2011 May; 21(5):699-715. PubMed ID: 21428846
[TBL] [Abstract][Full Text] [Related]
6. Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas.
Dujardin JC; González-Pacanowska D; Croft SL; Olesen OF; Späth GF
Trends Parasitol; 2010 Aug; 26(8):395-403. PubMed ID: 20538522
[TBL] [Abstract][Full Text] [Related]
7. Parasitology. Drugs to combat tropical protozoan parasites.
Gelb MH; Hol WG
Science; 2002 Jul; 297(5580):343-4. PubMed ID: 12130767
[No Abstract] [Full Text] [Related]
8. Management of trypanosomiasis and leishmaniasis.
Barrett MP; Croft SL
Br Med Bull; 2012; 104(1):175-96. PubMed ID: 23137768
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Potential of Natural Products as Antiparasitic Agents for Neglected Tropical Diseases.
Orosco D; Mendoza AR; Meléndez CM
Curr Top Med Chem; 2024; 24(2):89-108. PubMed ID: 37842892
[TBL] [Abstract][Full Text] [Related]
10. Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease.
Future Med Chem; 2013 Oct; 5(15):1709-18. PubMed ID: 24144408
[TBL] [Abstract][Full Text] [Related]
11. Infectious diseases. Overcoming neglect of kinetoplastid diseases.
Bilbe G
Science; 2015 May; 348(6238):974-6. PubMed ID: 26023124
[No Abstract] [Full Text] [Related]
12. Computer-Aided Drug Design Using Sesquiterpene Lactones as Sources of New Structures with Potential Activity against Infectious Neglected Diseases.
Herrera Acevedo C; Scotti L; Feitosa Alves M; Formiga Melo Diniz MF; Scotti MT
Molecules; 2017 Jan; 22(1):. PubMed ID: 28054952
[TBL] [Abstract][Full Text] [Related]
13. Leishmanicidal and Trypanocidal Activity of Metal Complexes with 1,2,4-Triazolo[1,5-a]pyrimidines: Insights on their Therapeutic Potential against Leishmaniasis and Chagas Disease.
Salas JM; Caballero AB; Esteban-Parra GM; Méndez-Arriaga JM
Curr Med Chem; 2017; 24(25):2796-2806. PubMed ID: 28521698
[TBL] [Abstract][Full Text] [Related]
14. Hybrid Molecules: Promising Compounds for the Development of New Treatments Against Leishmaniasis and Chagas Disease.
Cardona-G W; Yepes AF; Herrera-R A
Curr Med Chem; 2018; 25(30):3637-3679. PubMed ID: 29521209
[TBL] [Abstract][Full Text] [Related]
15. Strategies for the design of orally bioavailable antileishmanial treatments.
Pham TT; Loiseau PM; Barratt G
Int J Pharm; 2013 Sep; 454(1):539-52. PubMed ID: 23871737
[TBL] [Abstract][Full Text] [Related]
16. Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option.
Sbaraglini ML; Vanrell MC; Bellera CL; Benaim G; Carrillo C; Talevi A; Romano PS
Curr Top Med Chem; 2016; 16(19):2201-22. PubMed ID: 26881713
[TBL] [Abstract][Full Text] [Related]
17. Antileishmanial and antitrypanosomal activity of symmetrical dibenzyl-substituted α,β-unsaturated carbonyl-based compounds.
Alkhaldi AA; de Koning HP; Bukhari SNA
Drug Des Devel Ther; 2019; 13():1179-1185. PubMed ID: 31118564
[No Abstract] [Full Text] [Related]
18. Antiprotozoal compounds: state of the art and new developments.
Astelbauer F; Walochnik J
Int J Antimicrob Agents; 2011 Aug; 38(2):118-24. PubMed ID: 21549569
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of arylsubstituted imidazoles derivatives as antiprotozoal agents and docking studies on sterol 14α-demethylase (CYP51) from Trypanosoma cruzi, Leishmania infantum, and Trypanosoma brucei.
Rojas Vargas JA; López AG; Pérez Y; Cos P; Froeyen M
Parasitol Res; 2019 May; 118(5):1533-1548. PubMed ID: 30903349
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.
Gilbert IH
Biochim Biophys Acta; 2002 Jul; 1587(2-3):249-57. PubMed ID: 12084467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
